Can’t prove otherwise right now other than to say they were aware of the clinicaltrials update situation for a long time and made a decision on when to do it perhaps based on what FDA was doing. I believe when the story gets told it will be proven to be other than a blunder by management based on the circumstances NWBO was facing. I also believe they realized the bears would take advantage any way they tried to update until FDA firmed up it’s position in guidance or publication of data occurred. FDA still has not put ECA guidance in stone. Is it because they want to approve first then update? That kind of approach certainly doesn’t help the company or it’s investors now does it. Outside influence or just part of “the process”? Best wishes.
News 
Market Data 
Discover 
